Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SLIMMER

SLIMMER

Ecnoglutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ecnoglutide
Population
obesity
Official title
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Phase
3
Registry status
completed · 2023-04 → 2024-06
Participants
664
Duration
48 weeks
Registry
NCT05813795

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
1.2 mgobesity china48664—−9.9 % vs −0.3 %
Δ −9.6 pp
———————press release
1.8 mgobesity china48664—−13.3 % vs −0.3 %
Δ −13.0 pp
———————press release
2.4 mgobesity china48664—−15.4 % vs −0.3 %
Δ −15.1 pp
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (3)
  • 1.2 mg · weight_tp · press release
    Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
  • 1.8 mg · weight_tp · press release
    Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3
  • 2.4 mg · weight_tp · press release
    Percent weight reduction, % | -9.9 | -13.3 | -15.4 | -0.3

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SLIMMER. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/slimmer/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.